Trait Information | |
Identifier | MONDO_0002898 |
Description | A malignant neoplasm involving the zone of skin [MONDO: DesignPattern] | Trait category |
Cancer
|
Synonyms |
15 synonyms
|
Mapped term(s) |
9 mapped terms
|
Child trait(s) | 6 child traits |
Polygenic Score (PGS) ID | PGS Name | PGS Publication (PGP) ID | Reported Trait | Mapped Trait(s) (Ontology) | Number of Variants | PGS Scoring File (FTP Link) |
---|---|---|---|---|---|---|
PGS000079 | CC_Melanoma | PGP000050 Graff RE et al. bioRxiv (2020) Pre | Melanoma | melanoma | 24 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000079/ScoringFiles/PGS000079.txt.gz |
PGS000118 | MEL29 | PGP000055 Fritsche LG et al. PLoS Genet (2019) | Melanoma | melanoma | 29 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000118/ScoringFiles/PGS000118.txt.gz |
PGS000119 | BCC32 | PGP000055 Fritsche LG et al. PLoS Genet (2019) | Basal cell carcinoma | basal cell carcinoma | 32 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000119/ScoringFiles/PGS000119.txt.gz |
PGS000120 | SCC10 | PGP000055 Fritsche LG et al. PLoS Genet (2019) | Squamous cell carcinoma | squamous cell carcinoma | 10 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000120/ScoringFiles/PGS000120.txt.gz |
PGS000157 | cGRS_Melanoma | PGP000075 Shi Z et al. Cancer Med (2019) | Melanoma | melanoma | 17 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000157/ScoringFiles/PGS000157.txt.gz |
PGS000339 | PRS22_CM | PGP000106 Law MH et al. Hum Mol Genet (2020) | Cutaneous melanoma | cutaneous melanoma | 22 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000339/ScoringFiles/PGS000339.txt.gz |
PGS000398 | PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 1,103,220 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000398/ScoringFiles/PGS000398.txt.gz |
PGS000399 | PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 6 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000399/ScoringFiles/PGS000399.txt.gz |
PGS000400 | PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 95 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000400/ScoringFiles/PGS000400.txt.gz |
PGS000401 | PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 1,111,490 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000401/ScoringFiles/PGS000401.txt.gz |
PGS000402 | PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 389 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000402/ScoringFiles/PGS000402.txt.gz |
PGS000403 | PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 16,316 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000403/ScoringFiles/PGS000403.txt.gz |
PGS000404 | PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 80 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000404/ScoringFiles/PGS000404.txt.gz |
PGS000405 | PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 1,119,238 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000405/ScoringFiles/PGS000405.txt.gz |
PGS000406 | PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 292 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000406/ScoringFiles/PGS000406.txt.gz |
PGS000407 | PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Skin cancer | skin carcinoma | 3,166 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000407/ScoringFiles/PGS000407.txt.gz |
PGS000408 | PRSWEB_PHECODE172.1_20001-1059_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 10 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000408/ScoringFiles/PGS000408.txt.gz |
PGS000409 | PRSWEB_PHECODE172.1_20001-1059_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 1,111,490 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000409/ScoringFiles/PGS000409.txt.gz |
PGS000410 | PRSWEB_PHECODE172.1_20001-1059_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 7 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000410/ScoringFiles/PGS000410.txt.gz |
PGS000411 | PRSWEB_PHECODE172.1_20001-1059_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 185 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000411/ScoringFiles/PGS000411.txt.gz |
PGS000412 | PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 16 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000412/ScoringFiles/PGS000412.txt.gz |
PGS000413 | PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 1,111,490 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000413/ScoringFiles/PGS000413.txt.gz |
PGS000414 | PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 21 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000414/ScoringFiles/PGS000414.txt.gz |
PGS000415 | PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 505 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000415/ScoringFiles/PGS000415.txt.gz |
PGS000416 | PRSWEB_PHECODE172.1_C43_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 9 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000416/ScoringFiles/PGS000416.txt.gz |
PGS000417 | PRSWEB_PHECODE172.1_C43_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 1,109,519 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000417/ScoringFiles/PGS000417.txt.gz |
PGS000418 | PRSWEB_PHECODE172.1_C43_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 9 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000418/ScoringFiles/PGS000418.txt.gz |
PGS000419 | PRSWEB_PHECODE172.1_C43_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 436 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000419/ScoringFiles/PGS000419.txt.gz |
PGS000420 | PRSWEB_PHECODE172.1_D03_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 147 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000420/ScoringFiles/PGS000420.txt.gz |
PGS000421 | PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 18 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000421/ScoringFiles/PGS000421.txt.gz |
PGS000422 | PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 18 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000422/ScoringFiles/PGS000422.txt.gz |
PGS000423 | PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 29 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000423/ScoringFiles/PGS000423.txt.gz |
PGS000424 | PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 27 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000424/ScoringFiles/PGS000424.txt.gz |
PGS000425 | PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 20 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000425/ScoringFiles/PGS000425.txt.gz |
PGS000426 | PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 20 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000426/ScoringFiles/PGS000426.txt.gz |
PGS000427 | PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 20 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000427/ScoringFiles/PGS000427.txt.gz |
PGS000428 | PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 20 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000428/ScoringFiles/PGS000428.txt.gz |
PGS000429 | PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 12 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000429/ScoringFiles/PGS000429.txt.gz |
PGS000430 | PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 1,119,238 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000430/ScoringFiles/PGS000430.txt.gz |
PGS000431 | PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 15 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000431/ScoringFiles/PGS000431.txt.gz |
PGS000432 | PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Melanomas of skin (diagnosis or history) | melanoma | 296 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000432/ScoringFiles/PGS000432.txt.gz |
PGS000433 | PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 108 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000433/ScoringFiles/PGS000433.txt.gz |
PGS000434 | PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 1,111,490 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000434/ScoringFiles/PGS000434.txt.gz |
PGS000435 | PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 446 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000435/ScoringFiles/PGS000435.txt.gz |
PGS000436 | PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 16,626 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000436/ScoringFiles/PGS000436.txt.gz |
PGS000437 | PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 63 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000437/ScoringFiles/PGS000437.txt.gz |
PGS000438 | PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 1,111,490 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000438/ScoringFiles/PGS000438.txt.gz |
PGS000439 | PRSWEB_PHECODE172.2_C44_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 467 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000439/ScoringFiles/PGS000439.txt.gz |
PGS000440 | PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 2,111 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000440/ScoringFiles/PGS000440.txt.gz |
PGS000441 | PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 77 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000441/ScoringFiles/PGS000441.txt.gz |
PGS000442 | PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 1,119,238 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000442/ScoringFiles/PGS000442.txt.gz |
PGS000443 | PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 177 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000443/ScoringFiles/PGS000443.txt.gz |
PGS000444 | PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Other non-epithelial cancer of skin | skin cancer | 7,231 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000444/ScoringFiles/PGS000444.txt.gz |
PGS000445 | PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 19 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000445/ScoringFiles/PGS000445.txt.gz |
PGS000446 | PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 1,111,490 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000446/ScoringFiles/PGS000446.txt.gz |
PGS000447 | PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 72 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000447/ScoringFiles/PGS000447.txt.gz |
PGS000448 | PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 183 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000448/ScoringFiles/PGS000448.txt.gz |
PGS000449 | PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 1,073,162 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000449/ScoringFiles/PGS000449.txt.gz |
PGS000450 | PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 8 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000450/ScoringFiles/PGS000450.txt.gz |
PGS000451 | PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 2,231 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000451/ScoringFiles/PGS000451.txt.gz |
PGS000452 | PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 28 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000452/ScoringFiles/PGS000452.txt.gz |
PGS000453 | PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 28 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000453/ScoringFiles/PGS000453.txt.gz |
PGS000454 | PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 27 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000454/ScoringFiles/PGS000454.txt.gz |
PGS000455 | PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 28 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000455/ScoringFiles/PGS000455.txt.gz |
PGS000456 | PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 30 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000456/ScoringFiles/PGS000456.txt.gz |
PGS000457 | PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 30 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000457/ScoringFiles/PGS000457.txt.gz |
PGS000458 | PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 23 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000458/ScoringFiles/PGS000458.txt.gz |
PGS000459 | PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Basal cell carcinoma | basal cell carcinoma | 24 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000459/ScoringFiles/PGS000459.txt.gz |
PGS000460 | PRSWEB_PHECODE172.22_20001-1062_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Squamous cell carcinoma | squamous cell carcinoma | 4,279,140 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000460/ScoringFiles/PGS000460.txt.gz |
PGS000461 | PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Squamous cell carcinoma | squamous cell carcinoma | 13 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000461/ScoringFiles/PGS000461.txt.gz |
PGS000462 | PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Squamous cell carcinoma | squamous cell carcinoma | 13 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000462/ScoringFiles/PGS000462.txt.gz |
PGS000463 | PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Squamous cell carcinoma | squamous cell carcinoma | 7 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000463/ScoringFiles/PGS000463.txt.gz |
PGS000464 | PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Squamous cell carcinoma | squamous cell carcinoma | 14 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000464/ScoringFiles/PGS000464.txt.gz |
PGS000465 | PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Squamous cell carcinoma | squamous cell carcinoma | 10 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000465/ScoringFiles/PGS000465.txt.gz |
PGS000466 | PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Squamous cell carcinoma | squamous cell carcinoma | 10 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000466/ScoringFiles/PGS000466.txt.gz |
PGS000467 | PRSWEB_PHECODE172.22_cSCC-Chahal_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Squamous cell carcinoma | squamous cell carcinoma | 6 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000467/ScoringFiles/PGS000467.txt.gz |
PGS000468 | PRSWEB_PHECODE172.22_cSCC-Chahal_PT_UKB_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Squamous cell carcinoma | squamous cell carcinoma | 9 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000468/ScoringFiles/PGS000468.txt.gz |
PGS000469 | PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Carcinoma in situ of skin | skin carcinoma in situ | 1,119,238 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000469/ScoringFiles/PGS000469.txt.gz |
PGS000470 | PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Carcinoma in situ of skin | skin carcinoma in situ | 5 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000470/ScoringFiles/PGS000470.txt.gz |
PGS000471 | PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608 | PGP000118 Fritsche LG et al. Am J Hum Genet (2020) | Carcinoma in situ of skin | skin carcinoma in situ | 7 | http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000471/ScoringFiles/PGS000471.txt.gz |
PGS Performance Metric ID (PPM ID) |
Evaluated Score |
PGS Sample Set ID (PSS ID) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
PGS Classification Metrics | Other Metrics | Covariates Included in the Model | PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|---|
PPM000199 | PGS000079 (CC_Melanoma) | PSS000118 | PGP000050 Graff RE et al. (2020) Pre |
Reported Trait: Melanoma | OR: 1.44 [1.41, 1.48] | — | — | Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, sex, 10 PCs. | Results from meta-analysis of GERA and UKB |
PPM000348 | PGS000118 (MEL29) | PSS000210 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Melanoma | OR: 1.5 [1.44, 1.55] | — | — | age, sex, genotyping array, first 4 genotype PCs | — |
PPM000347 | PGS000119 (BCC32) | PSS000211 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Skin cancer | OR: 1.4 [1.42, 1.48] | — | — | age, sex, genotyping array, first 4 genotype PCs | — |
PPM000346 | PGS000120 (SCC10) | PSS000211 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Skin cancer | OR: 1.3 [1.3, 1.34] | — | — | age, sex, genotyping array, first 4 genotype PCs | — |
PPM000345 | PGS000118 (MEL29) | PSS000211 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Skin cancer | OR: 1.2 [1.22, 1.36] | — | — | age, sex, genotyping array, first 4 genotype PCs | — |
PPM000344 | PGS000119 (BCC32) | PSS000207 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Skin cancer | OR: 1.32 [1.27, 1.36] | AUROC: 0.58 [0.56, 0.58] | — | age, sex, batch, PC1-4 | — |
PPM000343 | PGS000120 (SCC10) | PSS000207 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Skin cancer | OR: 1.34 [1.3, 1.38] | AUROC: 0.58 [0.57, 0.6] | — | age, sex, batch, PC1-4 | — |
PPM000342 | PGS000118 (MEL29) | PSS000207 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Skin cancer | OR: 1.3 [1.26, 1.34] | AUROC: 0.57 [0.56, 0.58] | — | age, sex, batch, PC1-4 | — |
PPM000341 | PGS000119 (BCC32) | PSS000209 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Basal cell carcinoma | OR: 1.65 [1.56, 1.75] | AUROC: 0.64 [0.62, 0.66] | — | age, sex, batch, PC1-4 | — |
PPM000340 | PGS000120 (SCC10) | PSS000208 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Squamous cell carcinoma | OR: 1.4 [1.31, 1.5] | AUROC: 0.59 [0.56, 0.61] | — | age, sex, batch, PC1-4 | — |
PPM000339 | PGS000118 (MEL29) | PSS000206 | PGP000055 Fritsche LG et al. (2019) |
Reported Trait: Melanoma | OR: 1.48 [1.41, 1.56] | AUROC: 0.61 [0.59, 0.62] | — | age, sex, batch, PC1-4 | — |
PPM000488 | PGS000157 (cGRS_Melanoma) | PSS000277 | PGP000075 Shi Z et al. (2019) |
Reported Trait: Melanoma | — | — | Odds Ratio (OR; high vs. average risk groups): 1.72 [1.37, 2.16] | — | — |
PPM000477 | PGS000157 (cGRS_Melanoma) | PSS000277 | PGP000075 Shi Z et al. (2019) |
Reported Trait: Melanoma | — | — | Mean realative risk: 1.2 [1.14, 1.26] Wilcoxon test (case vs. control) p-value: 5.99e-11 |
— | — |
PPM000922 | PGS000339 (PRS22_CM) | PSS000464 | PGP000106 Law MH et al. (2020) |
Reported Trait: Cutaneous melanoma in multiplex melanoma families | — | — | Difference of PRS (deltaPRS; unaffected melanoma family members vs. unrelated controls): 0.347 (0.104) | PCs (1-10) | *Sample overlap between the controls used in this analysis and score development |
PPM000921 | PGS000339 (PRS22_CM) | PSS000463 | PGP000106 Law MH et al. (2020) |
Reported Trait: Cutaneous melanoma in multiplex melanoma families | — | — | Difference of PRS (deltaPRS; melanoma family cases vs. unrelated controls): 0.505 (0.036) | PCs (1-10) | *Sample overlap between the controls used in this analysis and score development |
PPM001085 | PGS000400 (PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.395] β: 0.294 (0.0197) |
AUROC: 0.581 [0.57, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.2 [1.63, 2.98] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_P_5e-08_MGI_20200608 |
PPM001088 | PGS000403 (PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.359 [1.307, 1.413] β: 0.307 (0.0199) |
AUROC: 0.584 [0.573, 0.594] | Nagelkerke's Pseudo-R²: 0.0219 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.2, 2.27] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_LASSOSUM_MGI_20200608 |
PPM001091 | PGS000406 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.392 [1.339, 1.447] β: 0.331 (0.0199) |
AUROC: 0.591 [0.581, 0.602] | Nagelkerke's Pseudo-R²: 0.0249 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.51 [1.89, 3.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PT_MGI_20200608 |
PPM001095 | PGS000410 (PRSWEB_PHECODE172.1_20001-1059_PT_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.399 [1.327, 1.476] β: 0.336 (0.0272) |
AUROC: 0.578 [0.562, 0.594] | Nagelkerke's Pseudo-R²: 0.0239 Brier score: 0.0956 Odds Ratio (OR, top 1% vs. Rest): 2.65 [1.79, 3.93] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_20001-1059_PT_MGI_20200608 |
PPM001098 | PGS000413 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PRS-CS_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.27 [1.199, 1.346] β: 0.239 (0.0294) |
AUROC: 0.568 [0.552, 0.584] | Nagelkerke's Pseudo-R²: 0.0109 Brier score: 0.0964 Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.35, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PRS-CS_MGI_20200608 |
PPM001101 | PGS000416 (PRSWEB_PHECODE172.1_C43_P_5e-08_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.473 [1.394, 1.557] β: 0.388 (0.0282) |
AUROC: 0.598 [0.582, 0.613] | Nagelkerke's Pseudo-R²: 0.0297 Brier score: 0.0952 Odds Ratio (OR, top 1% vs. Rest): 2.88 [1.96, 4.21] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C43_P_5e-08_MGI_20200608 |
PPM001103 | PGS000418 (PRSWEB_PHECODE172.1_C43_PT_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.473 [1.394, 1.557] β: 0.388 (0.0282) |
AUROC: 0.598 [0.582, 0.613] | Nagelkerke's Pseudo-R²: 0.0297 Brier score: 0.0952 Odds Ratio (OR, top 1% vs. Rest): 2.88 [1.96, 4.21] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C43_PT_MGI_20200608 |
PPM001106 | PGS000421 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.453 [1.37, 1.541] β: 0.374 (0.03) |
AUROC: 0.6 [0.584, 0.616] | Nagelkerke's Pseudo-R²: 0.0257 Brier score: 0.0955 Odds Ratio (OR, top 1% vs. Rest): 2.39 [1.58, 3.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_MGI_20200608 |
PPM001110 | PGS000425 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.453 [1.369, 1.542] β: 0.374 (0.0304) |
AUROC: 0.601 [0.585, 0.617] | Nagelkerke's Pseudo-R²: 0.0255 Brier score: 0.0955 Odds Ratio (OR, top 1% vs. Rest): 2.54 [1.7, 3.8] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_MGI_20200608 |
PPM001118 | PGS000433 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.367 [1.31, 1.426] β: 0.312 (0.0215) |
AUROC: 0.584 [0.572, 0.598] | Nagelkerke's Pseudo-R²: 0.0215 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.73 [2.01, 3.72] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_P_5e-08_MGI_20200608 |
PPM001121 | PGS000436 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.305, 1.42] β: 0.308 (0.0216) |
AUROC: 0.584 [0.571, 0.596] | Nagelkerke's Pseudo-R²: 0.021 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.22 [1.61, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_LASSOSUM_MGI_20200608 |
PPM001124 | PGS000439 (PRSWEB_PHECODE172.2_C44_PT_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.348 [1.293, 1.407] β: 0.299 (0.0216) |
AUROC: 0.583 [0.57, 0.595] | Nagelkerke's Pseudo-R²: 0.0197 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.17 [1.57, 3.01] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PT_MGI_20200608 |
PPM001127 | PGS000442 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.417] β: 0.306 (0.0217) |
AUROC: 0.584 [0.572, 0.595] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.35 [1.71, 3.22] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PRS-CS_MGI_20200608 |
PPM001130 | PGS000445 (PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.334 [1.264, 1.409] β: 0.289 (0.0278) |
AUROC: 0.571 [0.555, 0.587] | Nagelkerke's Pseudo-R²: 0.0184 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.54 [1.72, 3.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_P_5e-08_MGI_20200608 |
PPM001132 | PGS000447 (PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.398 [1.322, 1.477] β: 0.335 (0.0282) |
AUROC: 0.591 [0.575, 0.607] | Nagelkerke's Pseudo-R²: 0.0237 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.5 [1.68, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PT_MGI_20200608 |
PPM001135 | PGS000450 (PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.079 [1.022, 1.139] β: 0.0759 (0.0278) |
AUROC: 0.504 [0.489, 0.52] | Nagelkerke's Pseudo-R²: 0.00145 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.882, 2.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PT_MGI_20200608 |
PPM001138 | PGS000453 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608) | PSS000568 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_UKB_20200608 |
PPM001142 | PGS000457 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608) | PSS000568 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.535 [1.493, 1.579] β: 0.429 (0.0144) |
AUROC: 0.617 [0.609, 0.625] | Nagelkerke's Pseudo-R²: 0.0322 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.11 [2.6, 3.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_UKB_20200608 |
PPM001145 | PGS000460 (PRSWEB_PHECODE172.22_20001-1062_LASSOSUM_MGI_20200608) | PSS000545 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.096 [1.025, 1.172] β: 0.0917 (0.0344) |
AUROC: 0.523 [0.503, 0.543] | Nagelkerke's Pseudo-R²: 0.00155 Brier score: 0.0996 Odds Ratio (OR, top 1% vs. Rest): 1.56 [0.892, 2.74] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_20001-1062_LASSOSUM_MGI_20200608 |
PPM001148 | PGS000463 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_MGI_20200608) | PSS000545 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.448 [1.356, 1.546] β: 0.37 (0.0335) |
AUROC: 0.593 [0.573, 0.613] | Nagelkerke's Pseudo-R²: 0.0268 Brier score: 0.0977 Odds Ratio (OR, top 1% vs. Rest): 3.74 [2.46, 5.68] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_MGI_20200608 |
PPM001151 | PGS000466 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_UKB_20200608) | PSS000569 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Squamous cell carcinoma | β: 0.283 (0.0138) OR: 1.327 [1.292, 1.364] |
AUROC: 0.57 [0.562, 0.578] | Nagelkerke's Pseudo-R²: 0.0146 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 1.75 [1.4, 2.18] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_UKB_20200608 |
PPM001154 | PGS000469 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608) | PSS000547 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.09 [1.001, 1.188] β: 0.0865 (0.0437) |
AUROC: 0.524 [0.499, 0.549] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.0939 Odds Ratio (OR, top 1% vs. Rest): 1.48 [0.703, 3.1] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PRS-CS_MGI_20200608 |
PPM001083 | PGS000398 (PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.042 [1.003, 1.082] β: 0.0407 (0.0195) |
AUROC: 0.51 [0.499, 0.521] | Nagelkerke's Pseudo-R²: 0.00028 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.7 [1.22, 2.38] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PRS-CS_MGI_20200608 |
PPM001084 | PGS000399 (PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.158 [1.116, 1.202] β: 0.147 (0.0189) |
AUROC: 0.513 [0.503, 0.523] | Nagelkerke's Pseudo-R²: 0.00545 Brier score: 0.148 Odds Ratio (OR, top 1% vs. Rest): 1.56 [1.12, 2.16] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_20001-1003_PT_MGI_20200608 |
PPM001086 | PGS000401 (PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.342 [1.291, 1.396] β: 0.294 (0.0199) |
AUROC: 0.581 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0202 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.67, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PRS-CS_MGI_20200608 |
PPM001087 | PGS000402 (PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.366 [1.314, 1.421] β: 0.312 (0.0198) |
AUROC: 0.586 [0.576, 0.597] | Nagelkerke's Pseudo-R²: 0.0224 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.23 [1.64, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_C3-SKIN_PT_MGI_20200608 |
PPM001089 | PGS000404 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.369 [1.317, 1.422] β: 0.314 (0.0196) |
AUROC: 0.584 [0.574, 0.594] | Nagelkerke's Pseudo-R²: 0.0226 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.3 [1.72, 3.09] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_P_5e-08_MGI_20200608 |
PPM001090 | PGS000405 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.338 [1.287, 1.391] β: 0.291 (0.0199) |
AUROC: 0.58 [0.57, 0.591] | Nagelkerke's Pseudo-R²: 0.0192 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.42 [1.81, 3.24] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_PRS-CS_MGI_20200608 |
PPM001092 | PGS000407 (PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608) | PSS000548 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Skin cancer | OR: 1.38 [1.328, 1.434] β: 0.322 (0.0197) |
AUROC: 0.586 [0.575, 0.597] | Nagelkerke's Pseudo-R²: 0.0245 Brier score: 0.146 Odds Ratio (OR, top 1% vs. Rest): 2.26 [1.69, 3.03] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172_UKBB-SAIGE-HRC-X172_LASSOSUM_MGI_20200608 |
PPM001093 | PGS000408 (PRSWEB_PHECODE172.1_20001-1059_P_5e-08_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.384 [1.311, 1.461] β: 0.325 (0.0276) |
AUROC: 0.576 [0.561, 0.593] | Nagelkerke's Pseudo-R²: 0.0217 Brier score: 0.0957 Odds Ratio (OR, top 1% vs. Rest): 2.25 [1.48, 3.42] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_20001-1059_P_5e-08_MGI_20200608 |
PPM001096 | PGS000411 (PRSWEB_PHECODE172.1_20001-1059_LASSOSUM_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.378 [1.308, 1.451] β: 0.32 (0.0265) |
AUROC: 0.571 [0.555, 0.587] | Nagelkerke's Pseudo-R²: 0.0222 Brier score: 0.0957 Odds Ratio (OR, top 1% vs. Rest): 2.0 [1.29, 3.09] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_20001-1059_LASSOSUM_MGI_20200608 |
PPM001099 | PGS000414 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PT_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.44 [1.363, 1.522] β: 0.365 (0.0283) |
AUROC: 0.593 [0.576, 0.609] | Nagelkerke's Pseudo-R²: 0.026 Brier score: 0.0954 Odds Ratio (OR, top 1% vs. Rest): 2.97 [2.02, 4.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_PT_MGI_20200608 |
PPM001100 | PGS000415 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_LASSOSUM_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.391 [1.318, 1.467] β: 0.33 (0.0272) |
AUROC: 0.578 [0.562, 0.595] | Nagelkerke's Pseudo-R²: 0.0227 Brier score: 0.0957 Odds Ratio (OR, top 1% vs. Rest): 2.34 [1.55, 3.53] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_LASSOSUM_MGI_20200608 |
PPM001102 | PGS000417 (PRSWEB_PHECODE172.1_C43_PRS-CS_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.228 [1.159, 1.3] β: 0.205 (0.0294) |
AUROC: 0.556 [0.541, 0.571] | Nagelkerke's Pseudo-R²: 0.00812 Brier score: 0.0965 Odds Ratio (OR, top 1% vs. Rest): 1.88 [1.2, 2.95] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C43_PRS-CS_MGI_20200608 |
PPM001104 | PGS000419 (PRSWEB_PHECODE172.1_C43_LASSOSUM_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.348 [1.279, 1.421] β: 0.299 (0.0268) |
AUROC: 0.565 [0.549, 0.583] | Nagelkerke's Pseudo-R²: 0.0188 Brier score: 0.0959 Odds Ratio (OR, top 1% vs. Rest): 1.93 [1.24, 3.0] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C43_LASSOSUM_MGI_20200608 |
PPM001105 | PGS000420 (PRSWEB_PHECODE172.1_D03_PT_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.066 [1.007, 1.128] β: 0.0639 (0.029) |
AUROC: 0.516 [0.5, 0.533] | Nagelkerke's Pseudo-R²: 0.00074 Brier score: 0.0969 Odds Ratio (OR, top 1% vs. Rest): 1.07 [0.603, 1.9] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_D03_PT_MGI_20200608 |
PPM001107 | PGS000422 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_UKB_20200608) | PSS000567 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.539 [1.454, 1.629] β: 0.431 (0.029) |
AUROC: 0.615 [0.599, 0.63] | Nagelkerke's Pseudo-R²: 0.0332 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.57 [1.75, 3.77] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_P_5e-08_UKB_20200608 |
PPM001108 | PGS000423 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | β: 0.394 (0.0301) OR: 1.484 [1.399, 1.574] |
AUROC: 0.608 [0.592, 0.623] | Nagelkerke's Pseudo-R²: 0.0289 Brier score: 0.0954 Odds Ratio (OR, top 1% vs. Rest): 2.93 [2.0, 4.3] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_MGI_20200608 |
PPM001109 | PGS000424 (PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_UKB_20200608) | PSS000567 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.563 [1.475, 1.656] β: 0.447 (0.0294) |
AUROC: 0.619 [0.603, 0.634] | Nagelkerke's Pseudo-R²: 0.035 Brier score: 0.0812 Odds Ratio (OR, top 1% vs. Rest): 3.12 [2.18, 4.47] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_GWAS-Catalog-r2019-05-03-X172.1_PT_UKB_20200608 |
PPM001111 | PGS000426 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_UKB_20200608) | PSS000567 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.551 [1.463, 1.643] β: 0.439 (0.0296) |
AUROC: 0.62 [0.604, 0.635] | Nagelkerke's Pseudo-R²: 0.0335 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.81 [1.93, 4.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_Melanoma-Ransohoff_P_5e-08_UKB_20200608 |
PPM001112 | PGS000427 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.453 [1.369, 1.542] β: 0.374 (0.0304) |
AUROC: 0.601 [0.585, 0.617] | Nagelkerke's Pseudo-R²: 0.0255 Brier score: 0.0955 Odds Ratio (OR, top 1% vs. Rest): 2.54 [1.7, 3.8] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_MGI_20200608 |
PPM001113 | PGS000428 (PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_UKB_20200608) | PSS000567 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.551 [1.463, 1.643] β: 0.439 (0.0296) |
AUROC: 0.62 [0.604, 0.635] | Nagelkerke's Pseudo-R²: 0.0335 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.81 [1.93, 4.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_Melanoma-Ransohoff_PT_UKB_20200608 |
PPM001114 | PGS000429 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_P_5e-08_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.503 [1.422, 1.589] β: 0.408 (0.0284) |
AUROC: 0.606 [0.591, 0.622] | Nagelkerke's Pseudo-R²: 0.0332 Brier score: 0.0951 Odds Ratio (OR, top 1% vs. Rest): 2.62 [1.77, 3.88] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_P_5e-08_MGI_20200608 |
PPM001116 | PGS000431 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PT_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.486 [1.405, 1.571] β: 0.396 (0.0285) |
AUROC: 0.604 [0.587, 0.62] | Nagelkerke's Pseudo-R²: 0.0312 Brier score: 0.0952 Odds Ratio (OR, top 1% vs. Rest): 2.97 [2.04, 4.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PT_MGI_20200608 |
PPM001117 | PGS000432 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_LASSOSUM_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.391 [1.318, 1.467] β: 0.33 (0.0273) |
AUROC: 0.582 [0.566, 0.599] | Nagelkerke's Pseudo-R²: 0.0228 Brier score: 0.0957 Odds Ratio (OR, top 1% vs. Rest): 1.99 [1.29, 3.07] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_LASSOSUM_MGI_20200608 |
PPM001119 | PGS000434 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.361 [1.304, 1.42] β: 0.308 (0.0217) |
AUROC: 0.586 [0.573, 0.598] | Nagelkerke's Pseudo-R²: 0.0208 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.99 [1.43, 2.78] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PRS-CS_MGI_20200608 |
PPM001120 | PGS000435 (PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.357 [1.301, 1.415] β: 0.305 (0.0215) |
AUROC: 0.584 [0.572, 0.597] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.7 [1.99, 3.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C3-OTHER-SKIN_PT_MGI_20200608 |
PPM001122 | PGS000437 (PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.352 [1.296, 1.409] β: 0.301 (0.0213) |
AUROC: 0.579 [0.566, 0.592] | Nagelkerke's Pseudo-R²: 0.0206 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.21 [1.6, 3.06] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_P_5e-08_MGI_20200608 |
PPM001123 | PGS000438 (PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.31 [1.256, 1.367] β: 0.27 (0.0216) |
AUROC: 0.575 [0.562, 0.587] | Nagelkerke's Pseudo-R²: 0.0162 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 1.79 [1.28, 2.51] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_PRS-CS_MGI_20200608 |
PPM001125 | PGS000440 (PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.351 [1.296, 1.409] β: 0.301 (0.0215) |
AUROC: 0.581 [0.569, 0.592] | Nagelkerke's Pseudo-R²: 0.0201 Brier score: 0.137 Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.87, 3.46] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_C44_LASSOSUM_MGI_20200608 |
PPM001126 | PGS000441 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.39 [1.333, 1.449] β: 0.329 (0.0214) |
AUROC: 0.586 [0.574, 0.599] | Nagelkerke's Pseudo-R²: 0.0241 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.65 [1.94, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_P_5e-08_MGI_20200608 |
PPM001128 | PGS000443 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.41 [1.352, 1.471] β: 0.344 (0.0216) |
AUROC: 0.591 [0.579, 0.603] | Nagelkerke's Pseudo-R²: 0.0259 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 2.89 [2.14, 3.92] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_PT_MGI_20200608 |
PPM001131 | PGS000446 (PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.291 [1.221, 1.366] β: 0.256 (0.0286) |
AUROC: 0.575 [0.559, 0.591] | Nagelkerke's Pseudo-R²: 0.0139 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.42 [0.871, 2.33] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_PRS-CS_MGI_20200608 |
PPM001133 | PGS000448 (PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.411 [1.335, 1.491] β: 0.344 (0.0282) |
AUROC: 0.587 [0.57, 0.604] | Nagelkerke's Pseudo-R²: 0.0254 Brier score: 0.108 Odds Ratio (OR, top 1% vs. Rest): 2.93 [2.03, 4.25] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1061_LASSOSUM_MGI_20200608 |
PPM001134 | PGS000449 (PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.093 [1.034, 1.155] β: 0.0888 (0.0282) |
AUROC: 0.525 [0.509, 0.54] | Nagelkerke's Pseudo-R²: 0.00141 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 1.65 [1.04, 2.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_PRS-CS_MGI_20200608 |
PPM001136 | PGS000451 (PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.144 [1.084, 1.208] β: 0.135 (0.0278) |
AUROC: 0.521 [0.506, 0.536] | Nagelkerke's Pseudo-R²: 0.00396 Brier score: 0.109 Odds Ratio (OR, top 1% vs. Rest): 2.44 [1.65, 3.62] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_20001-1073_LASSOSUM_MGI_20200608 |
PPM001137 | PGS000452 (PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.663 [1.57, 1.761] β: 0.508 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0487 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.53, 5.15] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_P_5e-08_MGI_20200608 |
PPM001139 | PGS000454 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.661 [1.568, 1.759] β: 0.507 (0.0293) |
AUROC: 0.632 [0.616, 0.647] | Nagelkerke's Pseudo-R²: 0.0489 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.79 [2.68, 5.35] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_MGI_20200608 |
PPM001140 | PGS000455 (PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608) | PSS000568 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.511 [1.47, 1.554] β: 0.413 (0.0142) |
AUROC: 0.611 [0.604, 0.619] | Nagelkerke's Pseudo-R²: 0.0301 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 2.8 [2.33, 3.36] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_BCC-Chahal_PT_UKB_20200608 |
PPM001141 | PGS000456 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.633 [1.541, 1.729] β: 0.49 (0.0293) |
AUROC: 0.63 [0.615, 0.646] | Nagelkerke's Pseudo-R²: 0.0456 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 3.95 [2.79, 5.58] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_P_5e-08_MGI_20200608 |
PPM001143 | PGS000458 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608) | PSS000544 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.634 [1.542, 1.732] β: 0.491 (0.0296) |
AUROC: 0.628 [0.612, 0.644] | Nagelkerke's Pseudo-R²: 0.0457 Brier score: 0.106 Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.86, 5.69] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_MGI_20200608 |
PPM001144 | PGS000459 (PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608) | PSS000568 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Basal cell carcinoma | OR: 1.528 [1.485, 1.572] β: 0.424 (0.0144) |
AUROC: 0.615 [0.608, 0.623] | Nagelkerke's Pseudo-R²: 0.0314 Brier score: 0.0813 Odds Ratio (OR, top 1% vs. Rest): 3.05 [2.55, 3.64] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.21_GWAS-Catalog-r2019-05-03-X172.21_PT_UKB_20200608 |
PPM001146 | PGS000461 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608) | PSS000545 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.491 [1.395, 1.593] β: 0.4 (0.0338) |
AUROC: 0.599 [0.579, 0.618] | Nagelkerke's Pseudo-R²: 0.0304 Brier score: 0.0974 Odds Ratio (OR, top 1% vs. Rest): 3.51 [2.29, 5.39] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_MGI_20200608 |
PPM001147 | PGS000462 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_UKB_20200608) | PSS000569 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.324 [1.288, 1.361] β: 0.28 (0.014) |
AUROC: 0.573 [0.564, 0.58] | Nagelkerke's Pseudo-R²: 0.0141 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.13 [1.74, 2.61] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_P_5e-08_UKB_20200608 |
PPM001149 | PGS000464 (PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_UKB_20200608) | PSS000569 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.332 [1.296, 1.369] β: 0.287 (0.014) |
AUROC: 0.575 [0.567, 0.582] | Nagelkerke's Pseudo-R²: 0.0147 Brier score: 0.082 Odds Ratio (OR, top 1% vs. Rest): 2.19 [1.79, 2.67] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_GWAS-Catalog-r2019-05-03-X172.22_PT_UKB_20200608 |
PPM001150 | PGS000465 (PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_MGI_20200608) | PSS000545 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.457 [1.365, 1.554] β: 0.376 (0.033) |
AUROC: 0.589 [0.57, 0.61] | Nagelkerke's Pseudo-R²: 0.0282 Brier score: 0.0976 Odds Ratio (OR, top 1% vs. Rest): 4.54 [3.07, 6.71] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_P_5e-08_MGI_20200608 |
PPM001152 | PGS000467 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_MGI_20200608) | PSS000545 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.43 [1.341, 1.525] β: 0.358 (0.0328) |
AUROC: 0.583 [0.564, 0.603] | Nagelkerke's Pseudo-R²: 0.0261 Brier score: 0.0978 Odds Ratio (OR, top 1% vs. Rest): 3.75 [2.49, 5.64] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_PT_MGI_20200608 |
PPM001153 | PGS000468 (PRSWEB_PHECODE172.22_cSCC-Chahal_PT_UKB_20200608) | PSS000569 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Squamous cell carcinoma | OR: 1.334 [1.299, 1.371] β: 0.288 (0.0138) |
AUROC: 0.571 [0.563, 0.579] | Nagelkerke's Pseudo-R²: 0.0151 Brier score: 0.0819 Odds Ratio (OR, top 1% vs. Rest): 1.93 [1.56, 2.39] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.22_cSCC-Chahal_PT_UKB_20200608 |
PPM001155 | PGS000470 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608) | PSS000547 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.308 [1.208, 1.417] β: 0.269 (0.0407) |
AUROC: 0.557 [0.531, 0.582] | Nagelkerke's Pseudo-R²: 0.0154 Brier score: 0.093 Odds Ratio (OR, top 1% vs. Rest): 2.45 [1.34, 4.45] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_PT_MGI_20200608 |
PPM001156 | PGS000471 (PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608) | PSS000547 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Carcinoma in situ of skin | OR: 1.401 [1.297, 1.513] β: 0.337 (0.0393) |
AUROC: 0.569 [0.541, 0.595] | Nagelkerke's Pseudo-R²: 0.0255 Brier score: 0.0923 Odds Ratio (OR, top 1% vs. Rest): 3.77 [2.24, 6.34] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.3_UKBB-SAIGE-HRC-X172.3_LASSOSUM_MGI_20200608 |
PPM001115 | PGS000430 (PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PRS-CS_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.219 [1.151, 1.292] β: 0.198 (0.0296) |
AUROC: 0.555 [0.54, 0.573] | Nagelkerke's Pseudo-R²: 0.00721 Brier score: 0.0965 Odds Ratio (OR, top 1% vs. Rest): 1.64 [1.01, 2.66] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_UKBB-SAIGE-HRC-X172.1_PRS-CS_MGI_20200608 |
PPM001094 | PGS000409 (PRSWEB_PHECODE172.1_20001-1059_PRS-CS_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.192 [1.126, 1.263] β: 0.176 (0.0292) |
AUROC: 0.547 [0.531, 0.563] | Nagelkerke's Pseudo-R²: 0.0061 Brier score: 0.0966 Odds Ratio (OR, top 1% vs. Rest): 1.94 [1.25, 3.02] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_20001-1059_PRS-CS_MGI_20200608 |
PPM001097 | PGS000412 (PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_P_5e-08_MGI_20200608) | PSS000543 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Melanomas of skin, dx or hx | OR: 1.414 [1.338, 1.495] β: 0.347 (0.0282) |
AUROC: 0.585 [0.569, 0.6] | Nagelkerke's Pseudo-R²: 0.0236 Brier score: 0.0955 Odds Ratio (OR, top 1% vs. Rest): 3.26 [2.26, 4.7] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.1_C3-MELANOMA-SKIN_P_5e-08_MGI_20200608 |
PPM001129 | PGS000444 (PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608) | PSS000546 | PGP000118 Fritsche LG et al. (2020) |
Reported Trait: Other non-epithelial cancer of skin | OR: 1.399 [1.341, 1.46] β: 0.336 (0.0216) |
AUROC: 0.59 [0.578, 0.601] | Nagelkerke's Pseudo-R²: 0.025 Brier score: 0.136 Odds Ratio (OR, top 1% vs. Rest): 3.5 [2.63, 4.65] |
age, sex, batch PCs 1-4 | Cancer PRSweb PheWAS Results: PRSWEB_PHECODE172.2_UKBB-SAIGE-HRC-X172.2_LASSOSUM_MGI_20200608 |
PGS Sample Set ID (PSS ID) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000567 | PheCode:172.1; ICD9:-; ICD10:C43.0, C43.1, C43.2, C43.3, C43.4, C43.5, C43.6, C43.7, C43.8, C43.9, D03.0, D03.1, D03.2, D03.3, D03.4, D03.5, D03.6, D03.7, D03.8, D03.9 | — | [
|
— | European | — | UKB | — |
PSS000568 | PheCode:172.21; ICD9:173, 173.0, 173.1, 173.2, 173.3, 173.4, 173.5, 173.6, 173.7, 173.8, 173.9; ICD10:C44.0, C44.1, C44.2, C44.3, C44.4, C44.5, C44.6, C44.7, C44.8, C44.9 | — | [
|
— | European | — | UKB | — |
PSS000569 | PheCode:172.22; ICD9:173, 173.0, 173.1, 173.2, 173.3, 173.4, 173.5, 173.6, 173.7, 173.8, 173.9; ICD10:C44.0, C44.1, C44.2, C44.3, C44.4, C44.5, C44.6, C44.7, C44.8, C44.9 | — | [
|
— | European | — | UKB | — |
PSS000463 | Unaffected family members from families with increased melaona risk. Recruited families were ranked as low-, medium- or high-risk using a risk index (T) that factored in the number of confirmed cases of melanoma versus number of unaffected family members, ages and year of birth | — | [ ,
46.28 % Male samples |
— | European | Australia | BATS, QFMP | — |
PSS000464 | Unaffected family members from families with increased melaona risk. Recruited families were ranked as low-, medium- or high-risk using a risk index (T) that factored in the number of confirmed cases of melanoma versus number of unaffected family members, ages and year of birth | — | [ ,
46.37 % Male samples |
— | European | Australia | BATS, QFMP | — |
PSS000206 | Melanomas of skin : ICD9- 172.0,172.1,172.2,172.3,172.4,172.5,172.6,172.7,172.8,172.9 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
PSS000207 | PheCode 172 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
PSS000208 | Squamous cell carcinoma: ICD9-173.02,173.12,173.22,173.32,173.42,173.52,173.62,173.72,173.82,173.92 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
PSS000209 | Basal cell carcinoma: ICD9-173.01,173.11,173.21,173.31,173.41,173.51,173.61,173.71,173.81,173.91 | — | [ ,
46.9 % Male samples |
Mean = 54.2 years Sd = 15.9 years |
European | — | MGI | — |
PSS000210 | PheCode 172.11 | — | [ ,
45.9 % Male samples |
Mean = 57.7 years Sd = 8.1 years |
European | White British Subset | UKB | — |
PSS000211 | PheCode 172 | — | [ ,
45.9 % Male samples |
Mean = 57.7 years Sd = 8.1 years |
European | White British Subset | UKB | — |
PSS000277 | Primary tumor samples from TCGA | — | [
|
Mean = 59.0 years Sd = 16.0 years |
European | — | TCGA | — |
PSS000277 | — | — | [
|
— | European | — | eMERGE | — |
PSS000543 | PheCode:172.1; ICD9CM:172.0, 172.1, 172.2, 172.3, 172.4, 172.5, 172.6, 172.7, 172.8, 172.9, V10.82; ICD10CM:C43, C43.0, C43.1, C43.10, C43.11, C43.12, C43.2, C43.20, C43.21, C43.22, C43.3, C43.30, C43.31, C43.39, C43.4, C43.5, C43.51, C43.52, C43.59, C43.6, C43.60, C43.61, C43.62, C43.7, C43.70, C43.71, C43.72, C43.8, C43.9, D03, D03.0, D03.1, D03.10, D03.11, D03.12, D03.2, D03.20, D03.21, D03.22, D03.3, D03.30, D03.39, D03.4, D03.5, D03.51, D03.52, D03.59, D03.6, D03.60, D03.61, D03.62, D03.7, D03.70, D03.71, D03.72, D03.8, D03.9 | — | [
|
— | European | — | MGI | — |
PSS000544 | PheCode:172.21; ICD9CM:173.01, 173.11, 173.21, 173.31, 173.41, 173.51, 173.61, 173.71, 173.81, 173.91; ICD10CM:C44.01, C44.111, C44.112, C44.119, C44.211, C44.212, C44.219, C44.310, C44.311, C44.319, C44.41, C44.510, C44.511, C44.519, C44.611, C44.612, C44.619, C44.711, C44.712, C44.719, C44.81, C44.91 | — | [
|
— | European | — | MGI | — |
PSS000545 | PheCode:172.22; ICD9CM:173.02, 173.12, 173.22, 173.32, 173.42, 173.52, 173.62, 173.72, 173.82, 173.92; ICD10CM:C44.02, C44.121, C44.122, C44.129, C44.221, C44.222, C44.229, C44.320, C44.321, C44.329, C44.42, C44.520, C44.521, C44.529, C44.621, C44.622, C44.629, C44.721, C44.722, C44.729, C44.82, C44.92 | — | [
|
— | European | — | MGI | — |
PSS000546 | PheCode:172.2; ICD9CM:173.00, 173.01, 173.02, 173.09, 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.22, 173.29, 173.30, 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.52, 173.59, 173.60, 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.79, 173.80, 173.81, 173.82, 173.89, 173.90, 173.91, 173.92, 173.99, 209.31, 209.32, 209.33, 209.34, 209.35, 209.36, V10.83; ICD10CM:C44.0, C44.00, C44.01, C44.02, C44.09, C44.1, C44.10, C44.101, C44.102, C44.109, C44.11, C44.111, C44.112, C44.119, C44.12, C44.121, C44.122, C44.129, C44.19, C44.191, C44.192, C44.199, C44.2, C44.20, C44.201, C44.202, C44.209, C44.21, C44.211, C44.212, C44.219, C44.22, C44.221, C44.222, C44.229, C44.29, C44.291, C44.292, C44.299, C44.30, C44.300, C44.301, C44.309, C44.31, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.39, C44.390, C44.391, C44.399, C44.4, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.51, C44.510, C44.511, C44.519, C44.52, C44.520, C44.521, C44.529, C44.59, C44.590, C44.591, C44.599, C44.6, C44.60, C44.601, C44.602, C44.609, C44.61, C44.611, C44.612, C44.619, C44.62, C44.621, C44.622, C44.629, C44.69, C44.691, C44.692, C44.699, C44.7, C44.70, C44.701, C44.702, C44.709, C44.71, C44.711, C44.712, C44.719, C44.72, C44.721, C44.722, C44.729, C44.79, C44.791, C44.792, C44.799, C44.8, C44.80, C44.81, C44.82, C44.89, C44.9, C44.90, C44.91, C44.92, C44.99, C4A, C4A.0, C4A.1, C4A.10, C4A.11, C4A.12, C4A.2, C4A.20, C4A.21, C4A.22, C4A.3, C4A.30, C4A.31, C4A.39, C4A.4, C4A.5, C4A.51, C4A.52, C4A.59, C4A.6, C4A.60, C4A.61, C4A.62, C4A.7, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9 | — | [
|
— | European | — | MGI | — |
PSS000547 | PheCode:172.3; ICD9CM:232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9; ICD10CM:D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |
PSS000548 | PheCode:172; ICD9CM:172.0, 172.1, 172.2, 172.3, 172.4, 172.5, 172.6, 172.7, 172.8, 172.9, 173.00, 173.01, 173.02, 173.09, 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.22, 173.29, 173.30, 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.52, 173.59, 173.60, 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.79, 173.80, 173.81, 173.82, 173.89, 173.90, 173.91, 173.92, 173.99, 209.31, 209.32, 209.33, 209.34, 209.35, 209.36, 232.0, 232.1, 232.2, 232.3, 232.4, 232.5, 232.6, 232.7, 232.8, 232.9, V10.82, V10.83; ICD10CM:C43, C43.0, C43.1, C43.10, C43.11, C43.12, C43.2, C43.20, C43.21, C43.22, C43.3, C43.30, C43.31, C43.39, C43.4, C43.5, C43.51, C43.52, C43.59, C43.6, C43.60, C43.61, C43.62, C43.7, C43.70, C43.71, C43.72, C43.8, C43.9, C44.0, C44.00, C44.01, C44.02, C44.09, C44.1, C44.10, C44.101, C44.102, C44.109, C44.11, C44.111, C44.112, C44.119, C44.12, C44.121, C44.122, C44.129, C44.19, C44.191, C44.192, C44.199, C44.2, C44.20, C44.201, C44.202, C44.209, C44.21, C44.211, C44.212, C44.219, C44.22, C44.221, C44.222, C44.229, C44.29, C44.291, C44.292, C44.299, C44.30, C44.300, C44.301, C44.309, C44.31, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.39, C44.390, C44.391, C44.399, C44.4, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.51, C44.510, C44.511, C44.519, C44.52, C44.520, C44.521, C44.529, C44.59, C44.590, C44.591, C44.599, C44.6, C44.60, C44.601, C44.602, C44.609, C44.61, C44.611, C44.612, C44.619, C44.62, C44.621, C44.622, C44.629, C44.69, C44.691, C44.692, C44.699, C44.7, C44.70, C44.701, C44.702, C44.709, C44.71, C44.711, C44.712, C44.719, C44.72, C44.721, C44.722, C44.729, C44.79, C44.791, C44.792, C44.799, C44.8, C44.80, C44.81, C44.82, C44.89, C44.9, C44.90, C44.91, C44.92, C44.99, C4A, C4A.0, C4A.1, C4A.10, C4A.11, C4A.12, C4A.2, C4A.20, C4A.21, C4A.22, C4A.3, C4A.30, C4A.31, C4A.39, C4A.4, C4A.5, C4A.51, C4A.52, C4A.59, C4A.6, C4A.60, C4A.61, C4A.62, C4A.7, C4A.70, C4A.71, C4A.72, C4A.8, C4A.9, D03, D03.0, D03.1, D03.10, D03.11, D03.12, D03.2, D03.20, D03.21, D03.22, D03.3, D03.30, D03.39, D03.4, D03.5, D03.51, D03.52, D03.59, D03.6, D03.60, D03.61, D03.62, D03.7, D03.70, D03.71, D03.72, D03.8, D03.9, D04, D04.0, D04.1, D04.10, D04.11, D04.12, D04.2, D04.20, D04.21, D04.22, D04.3, D04.30, D04.39, D04.4, D04.5, D04.6, D04.60, D04.61, D04.62, D04.7, D04.70, D04.71, D04.72, D04.8, D04.9 | — | [
|
— | European | — | MGI | — |
PSS000118 | Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 25010 | — | [ ,
46.0 % Male samples |
Mean = 58.0 years | European | — | GERA, UKB | — |